Skip to content
Peptigraph home
Shop Peptides50% off*

Can women take retatrutide?

Women were enrolled in the trials. In the large trial in adults with obesity and diabetes, 554 of 1152 participants (48%) were female.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Women were enrolled in the trials. In the large trial in adults with obesity and diabetes, 554 of 1152 participants (48%) were female.[1]

In the monotherapy trial, 296 participants (55%) were female.[2]

More detail

In the dose-finding diabetes trial, 156 participants (56%) were female.[3]

The obesity dose-finding trial excluded women who were pregnant, breast-feeding or planning pregnancy, and those of childbearing potential not using adequate contraception.[4]

A meta-regression across several weight-loss drugs, retatrutide among them, found enhanced outcomes in cohorts with mostly female participants; this is a pooled finding, not a retatrutide-only one.[5]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can you build muscle on retatrutide?Can you drink alcohol while on retatrutide?

More on Retatrutide

Retatrutide overview

Sources

  1. 1Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  2. 2Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  3. 3Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  4. 4A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  5. 5Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring, Md.) · 2025PMID 40685589Accessed 2 Oct 2026

Found an error? Report a correction.